Calluna Pharma AS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Calluna Pharma AS - overview
Established
2024
Location
Oslo, -, Norway
Primary Industry
Biotechnology
About
Based in Oslo, Norway, and founded in 2024, Calluna Pharma AS, formed from the merger of Oxitope Pharma and Arxx Therapeutics, operates as a clinical-stage biotechnology company. In January 2024, the firm raised EUR 75 million in series A funding led by investor Forbion, with participation from other investors Sarsia Management, P53, and Investinor. The firm as of January 2024, is led by its Chairman, Marco Boorsma, and CEO, John Montana. The company offers therapeutic solutions to improve patient outcomes in diseases like inflammatory and fibrotic diseases, where existing treatments are sub-optimal.
Calluna adopts a therapeutic approach and precision targets upstream innate immune amplifiers developing a pipeline of therapeutic antibodies to restore tissue homeostasis and disrupt disease progression. Spearheading their portfolio is CAL101, a monoclonal antibody designed to neutralize S100A4, offering hope to patients with conditions like idiopathic pulmonary fibrosis, chronic kidney disease, and severe asthma. Other 3 therapies in the pipeline of the firm include CAL102, CAL103, and CAL104 for MI reperfusion injury, chronic pipeline, and chronic indication respectively. The company plans to utilize the January 2024 funding to develop novel therapies for inflammatory and fibrotic diseases.
Current Investors
Forbion, Sarsia, Investinor
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.callunapharma.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Calluna Pharma AS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Completed | Arxx Therapeutics AS, Oxitope Pharma B.V. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.